Johnson & Johnson posted a 9.1% increase in sales of $19.5 billion for the second quarter of 2014. Positive contributors to operational results were sales of Neutrogena and Aveeno skin care products; baby care products; and international sales of Listerine mouthwash and feminine protection products, according to the company. Skin care sales rose 6.6% to $968 million, while baby care increased 3.6% to $607 million and oral care inched up 1.7% to $413 million.
Operational results increased 9.4% and the negative impact of currency was 0.3%. Domestic sales increased 14.9%. International sales increased 4.4%, reflecting operational growth of 5.0% and a negative currency impact of 0.6%.
"Our strong second-quarter results reflect the continued success of our new product launches and the progress we have made in achieving our near-term priorities," said Alex Gorsky, chairman and chief executive officer. "Significant advancements are being made in the treatment options and access to care for patients and customers around the world. Our diversified business model, focus on long-term growth drivers and talented colleagues position us well in this evolving and dynamic global health care market."
Worldwide consumer sales of $3.7 billion for the second quarter represented an increase of 2.4% versus the prior year consisting of an operational increase of 3.6% and a negative impact from currency of 1.2%. Domestic sales decreased 0.5% primarily reflecting the divestiture of the sanitary protection business. International sales increased 3.9%, which reflected an operational increase of 5.8% and a negative currency impact of 1.9%.